First filing for Medivation's promising prostate cancer drug enzalutamide
This article was originally published in Scrip
Executive Summary
Medivation has made the first regulatory filing for its androgen receptor signalling inhibitor enzalutamide (MDV3100), in the US for use in patients with progressive castration-resistant prostate cancer who have already received docetaxel-based chemotherapy.